title: Expression of aryl hydrocarbon receptor in relation to p53 status and clinicopathological parameters in breast cancer.
abstract: The aryl hydrocarbon receptor (AhR) is a ligand activated transcription factor implicated in multiple cellular processes and its expression has been shown to play a critical role in tumorigenesis. However, the role of AhR in tumorigenesis of breast cancer remains unclear. In the current study, we investigated the expression levels of AhR in breast lesions and assessing the correlation between AhR expression and clinicopathological variables using breast cancer tissue microarray. Meanwhile, 10 paired of fresh breast cancer and corresponding non-cancer samples were detected for AhR and p53 expression by Western blot, respectively. Results showed that AhR expression levels in breast cancer tissues were significantly higher than that in the non-cancer tissues. AhR expression was associated with the pathological type and P53 status, but not patients age, tumor grade and TNM, as well as ER, PR, C-erbB2, Ki-67, AR, EGFR status. Moreover, Western blot data suggested a negative correlation between p53 protein and AhR protein expression levels. The results suggest that high levels of AhR were expressed in the majority of breast cancer tissues and closely associated with P53 status and histological types of breast cancer. AHR and its abnormal expression may play an important role in multiple stages of breast cancer progression.
authors.affiliation: Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine Shanghai 200040, China.
authors.forename: Zheng-Dong
authors.initials: ZD
authors.lastname: Li
authors.affiliation: Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine Shanghai 200040, China.
authors.forename: Kai
authors.initials: K
authors.lastname: Wang
authors.affiliation: Shanghai TCM Hospital, Shanghai University of TCM Shanghai 200071, China.
authors.forename: Xin-Wei
authors.initials: XW
authors.lastname: Yang
authors.affiliation: Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine Shanghai 200040, China.
authors.forename: Zhi-Gang
authors.initials: ZG
authors.lastname: Zhuang
authors.affiliation: Tongji Hospital, Tongji University School of Medicine Shanghai 200092, China.
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Wang
authors.affiliation: Tongji Hospital, Tongji University School of Medicine Shanghai 200092, China.
authors.forename: Xiao-Wen
authors.initials: XW
authors.lastname: Tong
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D006801:Humans; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D018336:Receptors, Aryl Hydrocarbon / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D046888:Tissue Array Analysis; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D018336:Receptors, Aryl Hydrocarbon; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53; C508053:ERBB2 protein, human
keywords: AhR; breast cancer; immunohistochemistry; p53; tissue microarray